Multiple Myeloma study: Etentamig vs Iberdomide
Official title Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov ID: NCT06896916
What this study is testing
What is Etentamig?
Etentamig is an investigational medicine being studied as a potential treatment for relapsed or refractory multiple myeloma.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study checks for side effects and sees if the treatment changes how active the disease is.
- Who it's for
- Adults with multiple myeloma that has returned or stopped responding to other treatments.
- What's involved
- Participants get IV etentamig and oral iberdomide, with regular blood tests and health checks.
- Time commitment
- The study lasts about 10 years, requiring regular visits to a hospital or clinic.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Eastern Cooperative Oncology Group (ECOG) performance of 0 or 1.
- Must have confirmed diagnosis of Relapsed/Refractory Multiple Myeloma (RRMM) after the participant's last treatment, as outlined in the protocol.
- All participants must have measurable diseases per central laboratory as outlined in protocol
You likely can't join if
- Has received prior etentamig treatment.
- Prior exposure to BCMA-targeted therapy as noted in the protocol.
- Has received prior cereblon E3 ligase modulatory drug (CELMoD) (iberdomide or mezigdomide).
The study team makes the final eligibility decision.
Where it is enrolling
- Beverly Hills, California, United States
- Denver, Colorado, United States
- St Louis, Missouri, United States
- New Brunswick, New Jersey, United States
- New York, New York, United States
- Hillsborough, North Carolina, United States
- Seattle, Washington, United States
- Blacktown, New South Wales, Australia
- Wollongong, New South Wales, Australia
- Melbourne, Victoria, Australia
- Nedlands, Western Australia, Australia
- Toronto, Ontario, Canada
- Montreal, Quebec, Canada
- Nice, Alpes-Maritimes, France
- Marseille, Bouches-du-Rhone, France
- Lille, Hauts-de-France, France
- Tours, Indre-et-Loire, France
- Toulouse, Occitanie, France
- Kashiwa-shi, Chiba, Japan
- Kumamoto, Kumamoto, Japan
+ 6 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Beverly Hills, California, United States; Denver, Colorado, United States; St Louis, Missouri, United States; New Brunswick, New Jersey, United States; New York, New York, United States; Hillsborough, North Carolina, United States and 20 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.